Conclusion
Anosmia and dysgeusia are prevalent symptoms of COVID19 disease,
especially amongst females. Further cohort or case control studies are
needed to establish the association and risk factors of anosmia and
dysgeusia with the disease ideally involving a control group. Definitive
mechanism of action and diagnostic value of anosmia and dysgeusia remain
to be verified in future studies. Effective treatment regimen for
anosmia and dysgeusia post COVID should be investigated in randomised
controlled trials to enhance patient’s quality of life.